Since its inception within the Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (GMTEC) in 2017, SAIL has grown to serve more than 80 laboratories spanning basic and translational research. We  emerging technologies in the rapidly advancing fields of single-cell sequencing and imaging-based molecular profiling, in addition to providing robust analytical solutions.

MSK has incomparable resources—unparalleled clinical volume; preeminent clinical expertise; a wealth of experimental tools, including mouse and organoid models; and computational leadership. In this environment, SAIL technologies have been applied to a spectrum of the most pressing research questions, including the study of developmental processes, metastasis, immunotherapy, and wound healing. The SAIL team is continually innovating protocols to access extremely challenging clinical tissues and is involved in basic technological development. We participate in high-profile projects, such as the study of lung, colon and pancreatic cancer metastasis as part of the Human Tumor Atlas Network of the National Cancer Institute.